Upgrade to SI Premium - Free Trial

Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)

September 3, 2026 6:44 AM
Canaccord analyst Sumant Kulkami reiterated a Buy rating and $36.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst commented: "Our ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments